MedTrace Logo

Biomarkers to Predict Time to Plasma HIV RNA Rebound

NCT03001128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2024-12-13

No results posted yet for this study

Summary

The purpose of this study is to collect information about what happens when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals. We will also study the safety of pausing ART under close observation.

Conditions

  • HIV-1 Infection

Interventions

DRUG

Antiretroviral treatment pause

Antiretroviral treatment pause

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

    lead NETWORK

Principal Investigators

  • Jonathan Li, MD, MMS · Brigham and Women's Hospital ACTG CRS

  • David Smith, MD, MAS · University of California San Diego AVRC CRS

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-23
Primary Completion
2021-01-29
Completion
2021-01-29

Countries

  • United States
  • Puerto Rico
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03001128 on ClinicalTrials.gov